Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and Disease    2014, Vol. 5 Issue (6) : 419-429     DOI: 10.14336/AD.2014.0500419
Review Article |
Early-life Exposure to Endocrine Disrupting Chemicals and Later-life Health Outcomes: An Epigenetic Bridge?
Vaiserman* Alexander()
D.F. Chebotarev Institute of Gerontology, Kiev, Ukraine
Download: PDF(0 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    

A growing body of evidence demonstrates that adverse events early in development, and particularly during intrauterine life, may program risks for diseases in adult life. Increasing evidence has been accumulated indicating the important role of epigenetic regulation including DNA methylation, histone modifications and miRNAs in developmental programming. Among the environmental factors which play an important role in programming of chronic pathologies, the endocrine-disrupting chemicals (EDCs) that have estrogenic, anti-estrogenic, and anti-androgenic activity are of specific concern because the developing organism is extremely sensitive to perturbation by substances with hormone-like activity. Among EDCs, there are many substances that are constantly present in the modern human environment or are in widespread use, including dioxin and dioxin-like compounds, phthalates, agricultural pesticides, polychlorinated biphenyls, industrial solvents, pharmaceuticals, and heavy metals. Apart from their common endocrine active properties, several EDCs have been shown to disrupt developmental epigenomic programming. The purpose of this review is to provide a summary of recent research findings which indicate that exposure to EDCs during in-utero and/or neonatal development can cause long-term health outcomes via mechanisms of epigenetic memory.

Keywords endocrine-disrupting chemicals      developmental programming      epigenetics      adult-life disease     
Issue Date: 21 November 2014
E-mail this article
E-mail Alert
Articles by authors
Vaiserman* Alexander
Cite this article:   
Vaiserman* Alexander. Early-life Exposure to Endocrine Disrupting Chemicals and Later-life Health Outcomes: An Epigenetic Bridge?[J]. Aging and Disease, 2014, 5(6): 419-429.
URL:     OR
[1] Reynolds LP, Caton JS (2012). Role of the pre- and post-natal environment in developmental programming of health and productivity. Mol Cell Endocrinol, 354: 54-9.
[2] Bollati V, Baccarelli A (2010). Environmental epigenetics. Heredity (Edinb), 105: 105-112.
[3] Wong RL, Walker CL (2013). Molecular pathways: environmental estrogens activate nongenomic signaling to developmentally reprogram the epigenome. Clin Cancer Res, 19: 3732-3737.
[4] Schug TT, Janesick A, Blumberg B, Heindel JJ (2011). Endocrine disrupting chemicals and disease susceptibility. J Steroid Biochem Mol Biol, 127: 204-215.
[5] De Coster S, van Larebeke N (2012). Endocrine-disrupting chemicals: associated disorders and mechanisms of action. J Environ Public Health, 2012: 713696.
[6] Zoeller RT, Brown TR, Doan LL, Gore AC, Skakkebaek NE, Soto AM, Woodruff TJ, Vom Saal FS (2012). Endocrine-disrupting chemicals and public health protection: a statement of principles from The Endocrine Society. Endocrinology, 153: 4097-4110.
[7] Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, Zoeller RT, Gore AC (2009). Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev, 30: 293-342.
[8] Kundakovic M, Champagne FA. Epigenetic perspective on the developmental effects of bisphenol A (2011). Brain Behav Immun, 25: 1084-1093.
[9] Bernal AJ, Jirtle RL (2010). Epigenomic disruption: the effects of early developmental exposures. Birth Defects Res A Clin Mol Teratol, 88: 938-944.
[10] Barouki R, Gluckman PD, Grandjean P, Hanson M, Heindel JJ (2012). Developmental origins of non-communicable disease: implications for research and public health. Environ Health, 11: 42.
[11] Langley-Evans SC, Alexander B, McArdle HJ, Sloboda DM (2012). Developmental origins of health and disease. J Nutr Metab, 2012: 838640.
[12] O'Sullivan L, Combes AN, Moritz KM (2012). Epigenetics and developmental programming of adult onset diseases. Pediatr Nephrol, 27: 2175-2182.
[13] Lupu DS, Tint D, Niculescu MD (2012). Perinatal epigenetic determinants of cognitive and metabolic disorders. Aging Dis, 3: 444-453.
[14] Huidobro C, Fernandez AF, Fraga MF (2013). Aging epigenetics: Causes and consequences. Mol Aspects Med, 34: 765-781.
[15] Hussain N (2012). Epigenetic influences that modulate infant growth, development, and disease. Antioxid Redox Signal, 17: 224-236.
[16] Baccarelli A, Bollati V (2009). Epigenetics and environmental chemicals. Curr Opin Pediatr, 21: 243-251.
[17] Bergman Y, Cedar H (2013). DNA methylation dynamics in health and disease. Nat Struct Mol Biol, 20: 274-281.
[18] Musselman CA, Lalonde ME, Côté J, Kutateladze TG (2012). Perceiving the epigenetic landscape through histone readers. Nat Struct Mol Biol,19: 1218-1227.
[19] Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM, Zhang GZ (2011). Biological functions of microRNAs: a review. J Physiol Biochem, 67: 129-139.
[20] Thompson RF, Einstein FH (2010). Epigenetic basis for fetal origins of age–related disease. Journal of Women's. Health, 19: 581-587.
[21] Shi L, Wu J (2009). Epigenetic regulation in mammalian preimplantation embryo development. Reprod Biol Endocrinol, 7: 59.
[22] Hochberg Z, Feil R, Constancia M, Fraga M, Junien C, Carel JC, Boileau P, Le Bouc Y, Deal CL, Lillycrop K, Scharfmann R, Sheppard A, Skinner M, Szyf M, Waterland RA, Waxman DJ, Whitelaw E, Ong K, Albertsson–Wikland K (2011). Child health, developmental plasticity, and epigenetic programming. Endocr Rev, 32: 159-224.
[23] Hogg K, Price EM, Hanna CW, Robinson WP (2012). Prenatal and perinatal environmental influences on the human fetal and placental epigenome. Clin Pharmacol Ther, 92: 716-726.
[24] Li S, Hursting SD, Davis BJ, McLachlan JA, Barrett JC (2003). Environmental exposure, DNA methylation, and gene regulation: lessons from diethylstilbesterol-induced cancers. Ann NY Acad Sci, 983: 161-169.
[25] Ho SM, Tang WY, Belmonte dF, Prins GS (2006). Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res, 66: 5624-5632.
[26] Csaba G (2011). The biological basis and clinical significance of hormonal imprinting, an epigenetic process. Clin Epigenetics, 2: 187-196.
[27] Macon MB, Fenton SE (2013). Endocrine disruptors and the breast: early life effects and later life disease. J Mammary Gland Biol Neoplasia, 18: 43-61.
[28] Fleisch AF, Wright RO, Baccarelli AA (2012). Environmental epigenetics: a role in endocrine disease? J Mol Endocrinol, 49: R61-R67.
[29] Husain Q, Qayyum S (2013). Biological and enzymatic treatment of bisphenol A and other endocrine disrupting compounds: a review. Crit Rev Biotechnol, 33: 260-292.
[30] Ikezuki Y, Tsutsumi O, Takai Y, Kamei Y, Taketani Y (2002). Determination of bisphenol A concentrations in human biological fluids reveals significant early prenatal exposure. Hum Reprod, 17: 2839-2841.
[31] Doherty LF, Bromer JG, Zhou Y, Aldad TS, Taylor HS (2010). In utero exposure to diethylstilbestrol (DES) or bisphenol-A (BPA) increases EZH2 expression in the mammary gland: an epigenetic mechanism linking endocrine disruptors to breast cancer. Horm Cancer, 1: 146-155.
[32] Veiga-Lopez A, Luense LJ, Christenson LK, Padmanabhan V (2013). Developmental programming: gestational bisphenol-A treatment alters trajectory of fetal ovarian gene expression. Endocrinology, 154: 1873-1884.
[33] Abi Salloum B, Steckler TL, Herkimer C, Lee JS, Padmanabhan V (2013). Developmental programming: impact of prenatal exposure to bisphenol-A and methoxychlor on steroid feedbacks in sheep. Toxicol Appl Pharmacol, 268: 300-308.
[34] Ho SM, Tang WY, Belmonte de Frausto J, Prins GS (2006). Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res, 66: 5624-5632.
[35] Prins GS, Tang WY, Belmonte J, Ho SM (2008). Perinatal exposure to oestradiol and bisphenol A alters the prostate epigenome and increases susceptibility to carcinogenesis. Basic Clin Pharmacol Toxicol, 102: 134-138.
[36] Dolinoy DC, Huang D, Jirtle RL (2007). Maternal nutrient supplementation counteracts bisphenol A-induced DNA hypomethylation in early development. Proc Natl Acad Sci U S A, 104: 13056-13061.
[37] Smith CC, Taylor HS (2007). Xenoestrogen exposure imprints expression of genes (Hoxa10) required for normal uterine development. FASEB J, 21: 239-246.
[38] Bromer JG, Zhou Y, Taylor MB, Doherty L, Taylor HS (2010). Bisphenol-A exposure in utero leads to epigenetic alterations in the developmental programming of uterine estrogen response. FASEB J, 24: 2273-2280.
[39] Yaoi T, Itoh K, Nakamura K, Ogi H, Fujiwara Y, Fushiki S (2008). Genome-wide analysis of epigenomic alterations in fetal mouse forebrain after exposure to low doses of bisphenol A. Biochem Biophys Res Commun, 376: 563-567.
[40] Doshi T, Mehta SS, Dighe V, Balasinor N, Vanage G (2011). Hypermethylation of estrogen receptor promoter region in adult testis of rats exposed neonatally to bisphenol A. Toxicology, 289: 74-82.
[41] Varayoud J, Ramos JG, Bosquiazzo VL, Muñoz-de-Toro M, Luque EH (2008). Developmental exposure to Bisphenol A impairs the uterine response to ovarian steroids in the adult. Endocrinology, 149: 5848-5860.
[42] Wei J, Lin Y, Li Y, Ying C, Chen J, Song L, Zhou Z, Lv Z, Xia W, Chen X, Xu S (2011). Perinatal exposure to bisphenol A at reference dose predisposes offspring to metabolic syndrome in adult rats on a high-fat diet. Endocrinology, 152: 3049-3061.
[43] Alonso-Magdalena P, Vieira E, Soriano S, Menes L, Burks D, Quesada I, Nadal A (2010). Bisphenol A exposure during pregnancy disrupts glucose homeostasis in mothers and adult male offspring. Environ Health Perspect, 118: 1243-1250.
[44] Ma Y, Xia W, Wang DQ, Wan YJ, Xu B, Chen X, Li YY, Xu SQ (2013). Hepatic DNA methylation modifications in early development of rats resulting from perinatal BPA exposure contribute to insulin resistance in adulthood. Diabetologia, 56: 2059-2067.
[45] Weng YI, Hsu PY, Liyanarachchi S, Liu J, Deatherage DE, Huang YW, Zuo T, Rodriguez B, Lin CH, Cheng AL, Huang TH (2010). Epigenetic influences of low-dose bisphenol A in primary human breast epithelial cells. Toxicol Appl Pharmacol, 248: 111-121.
[46] Robboy SJ, Scully RE, Welch WR & Herbst AL (1977). Intrauterine diethylstilbestrol exposure and its consequences: pathologic characteristics of vaginal adenosis, clear cell adenocarcinoma, and related lesions. Archives of Pathology & Laboratory Medicine, 101: 1-5.
[47] Newbold RR (2004). Lessons learned from perinatal exposure to diethylstilbestrol. Toxicol Appl Pharmacol, 199: 142-150.
[48] Li S, Washburn KA, Moore R, Uno T, Teng C, Newbold RR, McLachlan JA, Negishi M (1997). Developmental exposure to diethylstilbestrol elicits demethylation of estrogen-responsive lactoferrin gene in mouse uterus. Cancer Res, 57: 4356-4359.
[49] Skinner MK (2011). Environmental epigenetic transgenerational inheritance and somatic epigenetic mitotic stability. Epigenetics, 6: 838-842.
[50] Bromer JG, Wu J, Zhou Y, Taylor HS (2009). Hypermethylation of homeobox A10 by in utero diethylstilbestrol exposure: an epigenetic mechanism for altered developmental programming. Endocrinology, 150: 3376-3382.
[51] Stouder C, Paoloni-Giacobino A (2011). Specific transgenerational imprinting effects of the endocrine disruptor methoxychlor on male gametes. Reproduction, 141: 207-216.
[52] Armenti AE, Zama AM, Passantino L, Uzumcu M (2008). Developmental methoxychlor exposure affects multiple reproductive parameters and ovarian folliculogenesis and gene expression in adult rats. Toxicol Appl Pharmacol, 233: 286-296.
[53] Zama AM, Uzumcu M (2009). Fetal and neonatal exposure to the endocrine disruptor methoxychlor causes epigenetic alterations in adult ovarian genes. Endocrinology, 150: 4681-4691.
[54] Vadhana MS, Carloni M, Nasuti C, Fedeli D, Gabbianelli R (2011). Early life permethrin insecticide treatment leads to heart damage in adult rats. Exp Gerontol, 46: 731-738.
[55] Carloni M, Nasuti C, Fedeli D, Montani M, Amici A, Vadhana MS, Gabbianelli R (2012). The impact of early life permethrin exposure on development of neurodegeneration in adulthood. Exp Gerontol, 47: 60-66.
[56] Fedeli D, Montani M, Carloni M, Nasuti C, Amici A, Gabbianelli R (2012). Leukocyte Nurr1 as peripheral biomarker of early-life environmental exposure to permethrin insecticide. Biomarkers, 17: 604-609.
[57] Anway MD, Cupp AS, Uzumcu M, Skinner MK (2005). Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science, 308: 1466-1469.
[58] Anway MD, Leathers C, Skinner MK (2006). a). Endocrine disruptor vinclozolin induced epigenetic transgenerational adult-onset disease. Endocrinology, 147: 5515-5523.
[59] Anway MD, Memon MA, Uzumcu M, Skinner MK (2006). b). Transgenerational effect of the endocrine disruptor vinclozolin on male spermatogenesis. J. Androl. Nov-Dec, 27: 868-879.
[60] Anway MD, Rekow SS, Skinner MK (2008). Comparative anti-androgenic actions of vinclozolin and flutamide on transgenerational adult onset disease and spermatogenesis. Reprod Toxicol, 26: 100-106.
[61] Anway MD, Skinner MK (2008). Transgenerational effects of the endocrine disruptor vinclozolin on the prostate transcriptome and adult onset disease. Prostate, 68: 517-529.
[62] Nilsson EE, Anway MD, Stanfield J, Skinner MK (2008). Transgenerational epigenetic effects of the endocrine disruptor vinclozolin on pregnancies and female adult onset disease. Reproduction, 135: 713-721.
[63] Stouder C, Paoloni-Giacobino A (2010). Transgenerational effects of the endocrine disruptor vinclozolin on the methylation pattern of imprinted genes in the mouse sperm. Reproduction, 139: 373-379.
[64] Schneider S, Kaufmann W, Buesen R, van Ravenzwaay B (2008). Vinclozolin--the lack of a transgenerational effect after oral maternal exposure during organogenesis. Reprod Toxicol, 25: 352-360.
[65] Schneider S, Marxfeld H, Gröters S, Buesen R, van Ravenzwaay B (2013). Vinclozolin--no transgenerational inheritance of anti-androgenic effects after maternal exposure during organogenesis via the intraperitoneal route. Reprod Toxicol, 37: 6-14.
[66] Inawaka K, Kawabe M, Takahashi S, Doi Y, Tomigahara Y, Tarui H, Abe J, Kawamura S, Shirai T (2009). Maternal exposure to anti-androgenic compounds, vinclozolin, flutamide and procymidone, has no effects on spermatogenesis and DNA methylation in male rats of subsequent generations. Toxicol Appl Pharmacol, 237: 178-187.
[67] Chang HS, Anway MD, Rekow SS, Skinner MK (2006). Transgenerational epigenetic imprinting of the male germline by endocrine disruptor exposure during gonadal sex determination. Endocrinology, 147: 5524-5541.
[68] Guerrero-Bosagna C, Settles M, Lucker B, Skinner MK (2010). Epigenetic transgenerational actions of vinclozolin on promoter regions of the sperm epigenome. PLoS One, 5: e13100.
[69] Guerrero-Bosagna C, Covert TR, Haque MM, Settles M, Nilsson EE, Anway MD, Skinner MK (2012). Epigenetic transgenerational inheritance of vinclozolin induced mouse adult onset disease and associated sperm epigenome biomarkers. Reprod Toxicol, 34: 694-707.
[70] Somm E, Stouder C, Paoloni-Giacobino A (2013). Effect of developmental dioxin exposure on methylation and expression of specific imprinted genes in mice. Reprod Toxicol, 35: 150-155.
[71] Wu Q, Ohsako S, Ishimura R, Suzuki JS, Tohyama C (2004). Exposure of mouse preimplantation embryos to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) alters the methylation status of imprinted genes H19 and Igf2. Biol Reprod, 70: 1790-1797.
[72] Aragon AC, Kopf PG, Campen MJ, Huwe JK, Walker MK (2008). In utero and lactational 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure: effects on fetal and adult cardiac gene expression and adult cardiac and renal morphology. Toxicol Sci, 101: 321-330.
[73] Choi SS, Miller MA, Harper PA (2006). In utero exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin induces amphiregulin gene expression in the developing mouse ureter. Toxicol Sci, 94: 163-174.
[74] Ohsako S, Miyabara Y, Nishimura N, Kurosawa S, Sakaue M, Ishimura R, Sato M, Takeda K, Aoki Y, Sone H, Tohyama C, Yonemoto J (2001). Maternal exposure to a low dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) suppressed the development of reproductive organs of male rats: dose-dependent increase of mRNA levels of 5alpha-reductase type 2 in contrast to decrease of androgen receptor in the pubertal ventral prostate. Toxicol Sci, 60: 132-143.
[75] Rebourcet D, Odet F, Vérot A, Combe E, Meugnier E, Pesenti S, Leduque P, Déchaud H, Magre S, Le Magueresse-Battistoni B (2010). The effects of an in utero exposure to 2,3,7,8-tetrachloro-dibenzo-p-dioxin on male reproductive function: identification of Ccl5 as a potential marker. Int J Androl, 33: 413-424.
[76] Iavicoli I, Fontana L, Bergamaschi A (2009). The effects of metals as endocrine disruptors. J Toxicol Environ Health B Crit Rev, 12: 206-223.
[77] Wirth JJ, Mijal RS (2010). Adverse effects of low level heavy metal exposure on male reproductive function. Syst Biol Reprod Med, 56: 147-167.
[78] Kortenkamp A (2011). Are cadmium and other heavy metal compounds acting as endocrine disrupters? Met Ions Life Sci, 8: 305-317.
[79] Castillo P, Ibáñez F, Guajardo A, Llanos MN, Ronco AM (2012). Impact of cadmium exposure during pregnancy on hepatic glucocorticoid receptor methylation and expression in rat fetus. PLoS One, 7: e44139.
[80] Schneider JS, Kidd SK, Anderson DW (2013). Influence of developmental lead exposure on expression of DNA methyltransferases and methyl cytosine-binding proteins in hippocampus. Toxicol Lett, 217: 75-81.
[81] Faulk C, Barks A, Liu K, Goodrich JM, Dolinoy DC (2013). Early-life lead exposure results in dose- and sex-specific effects on weight and epigenetic gene regulation in weanling mice. Epigenomics, 5: 487-500.
[82] Doi T, Puri P, McCann A, Bannigan J, Thompson J (2011). Epigenetic effect of cadmium on global de novo DNA hypomethylation in the cadmium-induced ventral body wall defect (VBWD) in the chick model. Toxicol Sci, 120: 475-480.
[83] Kippler M, Engström K, Mlakar SJ, Bottai M, Ahmed S, Hossain MB, Raqib R, Vahter M, Broberg K (2013). Sex-specific effects of early life cadmium exposure on DNA methylation and implications for birth weight. Epigenetics, 8: 494-503.
[84] Fry RC, Navasumrit P, Valiathan C, Svensson JP, Hogan BJ, Luo M, Bhattacharya S, Kandjanapa K, Soontararuks S, Nookabkaew S, Mahidol C, Ruchirawat M, Samson LD (2007). Activation of inflammation/NF-kappaB signaling in infants born to arsenic-exposed mothers. PLoS Genet, 3: e207.
[85] Vaiserman AM (2012). Early-life epigenetic programming of human disease and aging. In: Tollefsbol T, editor. Epigenetics in human disease. New York: Academic Press, 545-567.
[1] Tia R. Tidwell,Kjetil Søreide,Hanne R. Hagland. Aging, Metabolism, and Cancer Development: from Peto’s Paradox to the Warburg Effect[J]. A&D, 2017, 8(5): 662-676.
[2] Haiping Zhao,Ziping Han,Xunming Ji,Yumin Luo. Epigenetic Regulation of Oxidative Stress in Ischemic Stroke[J]. A&D, 2016, 7(3): 295-306.
[3] Karen L. Saban,Herbert L. Mathews,Holli A. DeVon,Linda W. Janusek. Epigenetics and Social Context: Implications for Disparity in Cardiovascular Disease[J]. Aging and Disease, 2014, 5(5): 346-355.
Full text



Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail:
Powered by Beijing Magtech Co. Ltd